Tandem Diabetes Care (NASDAQ:TNDM) Upgraded by SVB Leerink to "Outperform"

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) was upgraded by SVB Leerink from a "market perform" rating to an "outperform" rating in a research note issued on Thursday, MarketBeat Ratings reports. The firm presently has a $45.00 target price on the medical device company's stock, up from their previous target price of $34.00. SVB Leerink's price target points to a potential upside of 26.55% from the company's current price.

TNDM has been the topic of several other research reports. StockNews.com raised Tandem Diabetes Care from a "sell" rating to a "hold" rating in a research report on Friday, April 19th. Citigroup increased their target price on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a "neutral" rating in a research report on Wednesday, April 3rd. Finally, Stifel Nicolaus increased their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a "buy" rating in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat.com, Tandem Diabetes Care presently has a consensus rating of "Hold" and an average price target of $39.45.

Tandem Diabetes Care Trading Up 1.3 %

TNDM traded up $0.44 during trading on Thursday, hitting $35.56. 1,568,049 shares of the stock were exchanged, compared to its average volume of 1,733,326. The firm has a 50 day simple moving average of $30.74 and a 200 day simple moving average of $25.26. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -10.34 and a beta of 1.12. Tandem Diabetes Care has a 1 year low of $13.82 and a 1 year high of $40.74. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last released its quarterly earnings data on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The firm had revenue of $196.80 million for the quarter, compared to analysts' expectations of $204.86 million. Tandem Diabetes Care had a negative return on equity of 31.48% and a negative net margin of 29.77%. As a group, equities analysts expect that Tandem Diabetes Care will post -1.62 EPS for the current year.

Hedge Funds Weigh In On Tandem Diabetes Care

A number of institutional investors have recently modified their holdings of TNDM. RiverPark Advisors LLC purchased a new position in shares of Tandem Diabetes Care during the 4th quarter valued at about $27,000. MCF Advisors LLC increased its stake in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company's stock valued at $36,000 after purchasing an additional 445 shares in the last quarter. Signaturefd LLC increased its stake in shares of Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company's stock valued at $50,000 after purchasing an additional 1,517 shares in the last quarter. Arcadia Investment Management Corp MI increased its stake in shares of Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company's stock valued at $66,000 after purchasing an additional 1,085 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its stake in shares of Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company's stock valued at $67,000 after purchasing an additional 1,099 shares in the last quarter.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.